NCT05744739View on ClinicalTrials.gov

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

August 20, 2024

Study Completion Date

April 23, 2030

Conditions
Acute Myeloid Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Tomivosertib

Given PO

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

EFFECTOR Therapeutics, Inc.

UNKNOWN

lead

Northwestern University

OTHER

NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter